Fairchem Organics schedules board meeting on 27 July to approve Q2 2026 unaudited results

What Fairchem Organics announced

Fairchem Organics Ltd (BSE: 543252) informed the Bombay Stock Exchange on 13 July 2026 that its Board of Directors will meet on 27 July 2026. The primary purpose of the meeting is to consider and approve the unaudited financial results for the quarter ended 30 June 2026. The announcement is a standard statutory intimation required under SEBI (Listing Obligations and Disclosure Requirements) regulations.

"The meeting of the Board of Directors of the Company is scheduled on 27/07/2026, inter alia, to consider and approve the Unaudited Financial Results for the Quarter ended June 30, 2026."

No financial figures or performance metrics were disclosed in the filing.

Board meeting specifics

• Date of meeting: 27 July 2026
• Time & venue: Not specified in the filing; typical practice is to hold the meeting at the registered office.
• Agenda: Primarily the approval of unaudited Q2 FY2026 results; the term inter alia suggests additional items may be discussed, but those are not detailed.
• Regulatory context: Companies listed on Indian exchanges must give at least a 48‑hour notice before a board meeting that will consider financial results. The notice is filed on BSE’s portal and becomes publicly accessible.

Key facts at a glance

Why this matters for investors

The filing signals that the company is on track to release its quarterly performance, albeit after the board’s formal approval. Investors typically await the approved results to assess revenue growth, profitability, and cash‑flow trends. Because the results are unaudited, they may be subject to adjustments after the audit, but the board’s sign‑off is a prerequisite for public dissemination. The absence of any disclosed figures means that market participants cannot yet gauge the quarter’s performance, but the scheduled date provides a clear timeline for when the information is expected.

Conclusion

Fairchem Organics has complied with regulatory norms by announcing a board meeting on 27 July 2026 to approve its unaudited financial results for the quarter ended 30 June 2026. No quantitative data were provided in the notice, so investors will need to await the post‑meeting release to evaluate the company’s financial health for the period.